Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Bangsberg
David R
DR
Mbarara University of Science and Technology, Massachusetts General Hospital Center for Global Health, Ragon Institute of MGH, MIT, and Harvard, and Harvard Medical School, USA. david_bangsberg@harvard.edu
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D023801:Directly Observed Therapy / Q000523:psychology*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir; D055118:Medication Adherence; D063065:Organophosphonates / Q000008:administration & dosage; D011744:Pyrimidinones / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage; D012646:Self Administration / Q000523:psychology; D018119:Stavudine / Q000008:administration & dosage; D000068698:Tenofovir; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D063065:Organophosphonates; D011744:Pyrimidinones; D003841:Deoxycytidine; D061466:Lopinavir; D000068698:Tenofovir; D018119:Stavudine; D000068679:Emtricitabine; D000225:Adenine; D019438:Ritonavir